Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Oct 16 - Oct 21
Lin, D., Qin, T., Wang, Y., Sun, X
Cerebrolysin's Position: Decades of clinical use across 40+ countries with established safety and efficacy data Meta-analyses and Cochrane systematic reviews the highest levels of clinical evidence Known limitations: complex mixture makes precise mechanism attribution difficult, not FDA-approved, requires IV/IM administration Represents validated but incrementally effective neurotrophic therapy Dihexa's Position: Exceptional mechanistic novelty HGF/c-Met potentiation at picomolar concentrations is a genuinely unique pharmacological finding if confirmed Entirely preclinical with no human data of any kind Foundational research compromised by expression of concern and retraction the core evidence base is actively questioned Theoretical safety concerns (c-Met oncogenesis) that have not been addressed experimentally Represents frontier neuroscience that has not survived the basic tests of scientific reproducibility For Researchers: Cerebrolysin offers a clinically validated tool for studying neurotrophic effects in humans, supported by the strongest available evidence
As the body doesnt make B12 or store it for a long time, supplementation may be required for those at risk of deficiency
For over 30 years, we've created cutting-edge patented technology that empowers individuals to take control of their wellness journey
A 62-year-old, female patient undergoes a hysterectomy under general anesthesia for uterine cancer
Not for use by persons under the age of 18
US$ 24.81
US$ 26.55
US$ 24.94
US$ 23.16
US$ 29.62
US$ 29.48
US$ 28.17
US$ 20.15
US$ 22.74
US$ 21.70
